ConductScience.org, home

Comparison · NCT02485301-deaths

GSK3390107A Group vs Placebo+GSK3390107A Group: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. GSK3390107A Group vs Placebo+GSK3390107A Group: deaths from any cause. Trial comparisons, record NCT02485301-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02485301-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0006630.0001170.00374wilson
Risk in group 20.001330.0003650.00484wilson
Risk difference, group 1 minus group 2-0.000667-0.004220.00256newcombe hybrid score
Risk ratio, group 1 over group 20.4980.04525.49log
Odds ratio, group 1 over group 20.4980.04515.5log
Number needed to treat, for one fewer death from any cause on GSK3390107A Group than on Placebo+GSK3390107A Group1,500from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1GSK3390107A Group
Healthy male or female subjects, aged 18 or older at the time of screening, who received one dose of the investigational GSK3390107A vaccine, at Day 0, administered intramuscularly, into the deltoid region of the arm.
11,509EG000
Group 2Placebo+GSK3390107A Group
Healthy male or female subjects, aged 18 or older at the time of screening, who received one dose of placebo at Day 0 and one dose of the investigational GSK3390107A vaccine at Month 6, administered intramuscularly, into the deltoid region of the arm.
21,504EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Solicited and unsolicited adverse events: during the 30-day (Days 0-29) post-vaccination period; SAEs: up to study end (Month 12).

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
NCT number
NCT02485301
Phases
PHASE2
Conditions
Virus Diseases
Interventions
GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A), Placebo
Lead sponsor
GlaxoSmithKline
Results first posted
2018-01-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02485301-deaths